Published January 1, 2017 | Version v1
Journal article Open

Epigallocatechin-3-gallate reduces the proliferation of benign prostatic hyperplasia cells via regulation of focal adhesions

  • 1. Uludag Univ, Fac Arts & Sci, Dept Mol Biol & Genet, TR-16059 Bursa, Turkey
  • 2. Manisa Celal Bayar Univ, Dept Med Biol, Fac Med, TR-45030 Manisa, Turkey

Description

Aims: Benign prostatic hyperplasia (BPH) is the most common urological disease that is characterized by the excessive growth of prostatic epithelial and stromal cells. Pharmacological therapy for BPH has limited use due to the many side effects so there is a need for new agents including natural compounds such as epigallocatechin-3-gallate (EGCG). This study was undertaken to assess the role of EGCG, suppressing the formation of BPH by reducing inflammation and oxidative stress, in cytoskeleton organization and ECM interactions via focal adhesions.

Files

bib-56ae7c64-6a4a-4f84-8608-43797fefef71.txt

Files (204 Bytes)

Name Size Download all
md5:1d518fbb663e00636b554453649f6487
204 Bytes Preview Download